title: [Fatal tuberculosis during treatment with ruxolitinib].
abstract: METHODS
  Two patients, 68 and 72 years old, were admitted with fever whilst under treatment with ruxolitinib for myelofibrosis. They had not been screened for latent tuberculosis infection (LTBI) and extensive tuberculosis was found in both patients. They died within weeks from complications of fulminant disease.
  
  
  CONCLUSIONS
  Doctors who prescribe ruxolitinib should be aware of the increased risk of infectious diseases like tuberculosis. Under immune suppression, tuberculosis often runs a disseminated course. The constitutional symptoms of myelofibrosis strongly resemble those of tuberculosis and the latter diagnosis should always be considered. Active and latent tuberculosis should be excluded and treated, if necessary, before giving ruxolitinib.
authors.affiliation: Gemeentelijke Gezondheidsdienst Amsterdam, afd. Tuberculosebestrijding, Amsterdam.
authors.forename: Sytze
authors.initials: S
authors.lastname: Keizer
authors.forename: Roald
authors.initials: R
authors.lastname: Gerritsen
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Jauw
authors.forename: Jeroen
authors.initials: J
authors.lastname: Janssen
authors.forename: Bart
authors.initials: B
authors.lastname: Koopman
authors.forename: Paul
authors.initials: P
authors.lastname: Bresser
mesh_terms: D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines
chemical_list: D000995:Antitubercular Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib